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Microfluidic squeezing for 
intracellular antigen loading 
in polyclonal B-cells as cellular 
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Brian Alejandro5, Clara Park2, Kirubel Frew6, Mavis Brefo1, Shirley Mao5, Megan Heimann3, 
Robert Langer3,5, Klavs Jensen5 & Darrell J Irvine1,2,3,6,7
B-cells are promising candidate autologous antigen-presenting cells (APCs) to prime antigen-specific 
T-cells both in vitro and in vivo. However to date, a significant barrier to utilizing B-cells as APCs is 
their low capacity for non-specific antigen uptake compared to “professional” APCs such as dendritic 
cells. Here we utilize a microfluidic device that employs many parallel channels to pass single cells 
through narrow constrictions in high throughput. This microscale “cell squeezing” process creates 
transient pores in the plasma membrane, enabling intracellular delivery of whole proteins from 
the surrounding medium into B-cells via mechano-poration. We demonstrate that both resting and 
activated B-cells process and present antigens delivered via mechano-poration exclusively to antigen-
specific CD8+T-cells, and not CD4+T-cells. Squeezed B-cells primed and expanded large numbers of 
effector CD8+ T-cells in vitro that produced effector cytokines critical to cytolytic function, including 
granzyme B and interferon-γ . Finally, antigen-loaded B-cells were also able to prime antigen-specific 
CD8+T-cells in vivo when adoptively transferred into mice. Altogether, these data demonstrate crucial 
proof-of-concept for mechano-poration as an enabling technology for B-cell antigen loading, priming 
of antigen-specific CD8+T-cells, and decoupling of antigen uptake from B-cell activation.
Antigen presenting cells (APCs) are a diverse subset of immune cells (including dendritic cells, mac-
rophages, B-cells) that capture foreign or self proteins and peptides from tissues, and activate adap-
tive immune cells to generate either an inflammatory or tolerogenic immune response against these 
antigens. Proteins are ingested by APCs in vivo via fluid-phase sampling of their surroundings or 
receptor-mediated ingestion of foreign microbes or dead cell debris. Ingested proteins are degraded into 
peptide fragments (antigens) which are processed and presented to T-cells together with costimulatory 
signals, instructing naïve T-cell activation based on the specific signals received by the APC and the 
antigens presented. Because of this critical role in T-cell activation, purified APCs loaded with antigen 
and activated ex vivo can be used to expand functional T-cells in culture (e.g., for adoptive T-cell therapy) 
or as effective cellular vaccines in vivo. Ex vivo manipulation of APCs has gained increasing interest as 
an alternative approach for generating specific types of immunity, particularly cytotoxic T lymphocytes 
(CTLs) in diseases such as cancer1–5 and HIV6–8 where targeted killing of pathogenic cells is critical and 
endogenous APC function is actively suppressed. Despite promising preclinical studies, clinical transla-
tion of cell-based vaccines has been hampered by multiple limitations and only one APC-based vaccine 
is currently FDA-approved9,10.
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Significant clinical research on cell-based vaccines has focused on dendritic cells (DCs), the so-called 
“professional” APCs because of their efficiency in priming CTLs, and their highly active extracellular 
protein uptake and antigen-processing capability. However, as a platform for clinical use, DCs are limited 
by their relative paucity in human blood11, complex subset heterogeneity12, short lifespan, and inability to 
proliferate. These challenges have led other cell types to also be considered for cell-based APC vaccines, 
including macrophages and B-cells13,14. In particular, B-cells have received interest for over a decade 
because of their unique properties as lymphocytes and their potential to overcome many limitations of 
DCs: B-cells are abundant in circulation (up to 0.5 million cells per mL of blood), can proliferate upon 
cellular activation, and efficiently home to secondary lymphoid organs when administered intravenously.
These potential advantages of B-cells as APCs are offset by limitations in the ability of B-cells to 
acquire and process antigen for priming of T-cells. B-cells express genetically rearranged B-cell recep-
tors (BCR), which on binding to their target antigen, promote antigen uptake and B-cell activation. 
While B-cells are able to internalize antigens via their BCRs and prime primary T-cell responses15,16, 
their uptake of non-specific antigens (i.e. antigens not recognized by their BCR) is poor compared to 
macrophages and DCs, which efficiently pinocytose and phagocytose antigens from their surroundings. 
Furthermore, priming of CTLs occurs through presentation of peptide by class I MHC molecules, which 
are normally only loaded with antigens located in the cytosol (where the class I MHC processing machin-
ery primarily resides). By contrast, proteins taken up via the BCR into endolysosomes tend to be directed 
to the MHC class II presentation pathway for presentation to CD4+T-cells17,18. Alternatively, B-cells and 
other professional APCs can load class I MHC molecules with peptides via cross presentation19–24, a pro-
cess whereby class I peptide-MHC complexes are produced from endocytosed antigens via proteasomal 
processing or vacuolar protein degradation25, but this process is generally very inefficient.
Many methods have been developed to increase antigen uptake and cross-presentation in B-cells. 
These strategies largely rely on targeting specific receptors for endocytic uptake16,20,26, activating B-cells 
combined with fluid-phase protein exposure to increase non-specific endocytosis16, delivering antigen 
as immune-stimulating complexes27, or generating fusion proteins to direct B-cell function28. These 
approaches are limited by the fact that antigen uptake is coupled to other changes in B-cell state mediated 
by signalling through the targeted receptor, meaning that antigen loading and B-cell activation cannot be 
separately tuned. For example, resting B-cells have been shown to be tolerogenic to naïve CD8+T-cells, a 
potentially useful property in treating autoimmunity29,30, and activation of the B-cell would be problem-
atic in such an application. Transfection of B-cells with DNA31,32, RNA33, or viral vectors34,35 encoding 
antigens has also shown promise, but is limited by a host of issues such as toxicity of electroporation, 
viral vector packaging capacity, transduction efficiency, stability, and anti-vector immunity.
Here, we demonstrate the application of a recently developed technology to facilitate direct cytosolic 
delivery of whole proteins into live B-cells by transient plasma membrane poration, induced as B-cells 
are passed through constrictions in microscale channels of a microfluidic device (mechano-poration)24,36. 
Using the well-defined model antigen ovalbumin (OVA), we demonstrate that delivery of whole protein 
via this method enables even resting B-cells to elicit robust priming of effector CTLs both in vitro and 
in vivo. To our knowledge, this novel method for whole protein delivery and antigen presentation by 
MHC class I is the first antigen delivery method in B-cells that easily decouples antigen loading from the 
process of B-cell activation, allowing these two processes to be separately tailored for immunogenic or 
tolerogenic vaccines. Cell squeezing provides an alternative modular platform that can prime autologous 
B-cells for in vitro CTL expansion as well as facilitate the development of B-cell-based vaccines.
Methods
Materials. TRITC- and Cascade Blue-labelled 3 kDa dextrans were purchased from Life Technologies. 
FITC-labelled 40 kDa dextran was purchased from Chondrex. Low endotoxin ovalbumin protein was 
purchased from Worthington Biochemical Corporation. CpG ODN 1826 (CpG B), CpG ODN 2395 
(CpG C), and LPS Escherichia coli K12 (LPS) were all purchased from Invivogen. Multimeric/meg-
aCD40L was purchased from Adipogen and Enzo Life Sciences.
Mice. All procedures were performed under an animal protocol approved by the Massachusetts 
Institute of Technology Committee on Animal Care (CAC) and in accordance with the guidelines for 
animal care in a Massachusetts Institute of Technology animal facility inspected by the US Department 
of Agriculture. Animals were cared for in the USDA-inspected MIT Animal Facility under federal, state, 
local and NIH guidelines for animal care. C57BL/6J (B6) mice were purchased from Jackson Labs. 
CD45.1 B6, OT-I Thy1.1, and OT-II strains were maintained in-house, with periodic genotyping from 
Transnetyx. All mice used were female and 6–12 wks of age.
Cell isolation. For B-cell isolation, spleens were harvested from mice and mashed through a 70 μ m 
cell strainer. Red blood cells were lysed and resting B-cells were isolated from the cell suspension with the 
B-Cell Isolation Kit, mouse (Miltenyi Biotec) following the manufacturer’s instructions. After isolation, 
B-cell suspensions were> 95% B220+ , as measured by flow cytometry. For CD8+T-cell isolation, spleens 
and inguinal lymph nodes were harvested and mashed. Following red blood cell lysis, CD8a+T-cells were 
isolated with the CD8a+T-cell Isolation Kit, mouse (Millenyi Biotec) according to the manufacturer’s 
instructions. CD4+T-cell isolation was performed with the CD4+T-cell Isolation Kit, mouse (Millenyi 
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Biotec) on spleen and inguinal lymph node suspensions. T-cells were consistently > 90% pure, as meas-
ured by CD8a or CD4 staining and flow cytometry. All cell culture was performed in T-cell media (RPMI 
with 10% FBS, penicillin-streptomycin, 1X sodium pyruvate) supplemented with 1 μ L/mL of 55 mM 
β -mercaptoethanol.
Protein delivery by cell squeezing. Delivery of whole protein antigen to resting B-cells was per-
formed using CellSqueeze, a commercial microfluidics device and pressure system (SQZ Biotech); chip 
designs used included 30-4 × 1, 10-4 × 1, and 30-5 × 5 where X-YxZ denotes Z sequential constriction 
channels of dimensions Xμ m long and Yμ m diameter. B-cells were suspended at 5 × 106 cells/mL in 
media with 100 μ g/mL of ovalbumin, 0.3 mg/mL TRITC- or Pacific Blue-labelled 3 kDa dextran, or 
0.3 mg/mL FITC-labelled 40 kDa dextran, and placed on ice. The microfluidics chips and holder set were 
also placed in an ice water bath until cold. The cell suspension was sent through the device in 200 μ L ali-
quots at 120 psi. Endocytosis control B-cells were prepared identically in medium with OVA, but did not 
go through the microfluidics device. After antigen loading, cells were allowed to rest at room temperature 
for 5 minutes and washed twice with PBS. To assess delivery efficiency, uptake of fluorescently-labelled 
dextrans was measured by flow cytometry as described below.
In vitro cell culture, activation & proliferation assays. To characterize in vitro activation of 
mechano-porated B-cells, cells that went through the SQZ device and endocytosis control cells were 
incubated in a 96-well U-bottom plate at 5 × 105 cells/mL with 5 μ M CpG B, 5 μ M CpG C, or 100 ng/mL 
LPS. Flow cytometry was performed at 24 and 48 hours to measure cell-surface levels of CD86, CD40, 
CD69, MHC class I, and MHC class II as described below.
For in vitro proliferation assays, purified OT-I CD8+ or OT-II CD4+T-cells were suspended at 107 cells/
mL and labelled with CFSE (5 μ M, Life Technologies) for 10 min. After one wash, T-cells and B-cells were 
plated at a 1:0.8 ratio in 200 μ L of T-cell media in a 96-well U-bottom plate. CpG B, CpG C, or LPS 
was added to the appropriate wells, and anti-CD3/CD28 Dynabeads (Life Technologies) were added to 
positive control wells at 1 bead/T-cell. Supernatant collection for cytokine analysis and flow cytometry 
to assess T-cell proliferation were performed on day 2 and day 4.
Luminex cytokine assay. Supernatants were collected and cleared of cells by centrifugation on days 
2 and 4 of in vitro proliferation assays. Cytokine concentrations were measured using a custom Milliplex 
MAP Mouse Cytokine/Chemokine Magnetic Bead assay (Millipore) following the manufacturer’s proto-
col with the following modifications: capture beads and detection antibodies were used at a 1/5x recom-
mended dilution. Assays were read on a Bio-plex FLEXMAP 3D (Bio-Rad).
In vivo proliferation assay. On day -1, 106 OT-I Thy1.1 CD8+resting T-cells labelled with CFSE 
(5 μ M) were injected retro-orbitally (r.o.) into C57BL/6 mice. The next day (day 0), animals were 
injected r.o. with 1–3 million CD45.1+B-cells that had been loaded with OVA using the microfluidics 
SQZ device the previous day and incubated overnight with 5 μ M CpG B, or were loaded with OVA by 
mechano-poration just prior to injection and not exposed to any TLR ligand. Animals were necropsied 
on day 4 and their spleens, inguinal lymph nodes, and cervical lymph nodes were harvested. The organs 
were mashed through a cell strainer. Single-cell suspensions were incubated with mouse anti-CD16/
CD32 (eBioscience) to reduce nonspecific antibody binding, and were stained with anti-CD8-APC, 
anti-B220-PE-Cy7, anti-CD45.1-PerCP-Cy5.5, and anti-Thy1.1-APC-Cy7. Flow cytometry to determine 
cell numbers and Thy1.1+ CD8+ T-cell CFSE dilution was performed.
Analysis of proliferation data. Normalized cell counts were calculated by dividing the number of 
surviving T-cells sampled in an experimental condition by the average number of surviving T-cells in the 
T-cell only control from the same experiment and assay timepoint. To calculate percent of input cells 
undergoing division and proliferation index, T-cells were first gated into generations according to their 
levels of CFSE dilution. The live T-cell count for each generation was divided by 2generation number to cal-
culate the number of original cells that had divided to create the cells in that generation gate. The percent 
of original cells divided was calculated by dividing the number of original cells that had divided by the 
total number of original cells. The proliferation index quantifies the mean number of divisions each 
divided cell underwent, and is given by i cells in generation total divided cellsi gen s∑ ( # )/∈ # ⁎ .
Flow cytometry. Cell populations were identified with anti-B220 (CD45R)-PE-Cy7 (RA3-6B2, 
eBioscience), anti-CD8a-APC (53-6.7, eBioscience), anti-CD4-AF647 (GK1.5, BioLegend), 
anti-CD45.1-PerCP-Cy5.5 (A20, BioLegend), and anti-Thy1.1 (CD90.1)-APC-Cy7 (OX-7, BioLegend). 
Cell surface activation marker levels were assessed by staining with anti-CD86-BV650 (GL-1, BioLegend), 
anti-CD40-APC (1C10, eBioscience), anti-CD69-PerCP-Cy5.5 (H1.2F3, BioLegend), anti-MHC I 
(H-2Kb)-PE (AF6-88.5.5.3, eBioscience), and anti-MHC II (I-A/I-E)-FITC (M5/114.15.2, eBioscience). 
All antibodies were used at a 1:500 dilution. Live-dead staining was performed with DAPI (3 μ M wash), 
or propidium iodide (PI; 1:50 dilution). Data collection was performed on a BD LSRFortessa, BD 
FACSCanto, or BD LSR II cytometer.
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Statistical analyses. One- or two-way analysis of variance (ANOVA) was performed between treat-
ment groups on normalized data. Holm Sidak multiple comparisons post-tests were performed, relevant 
comparisons were selected, and multiplicity adjusted P-values were reported. P-values less than or equal 
to 0.05 were considered statistically significant. All statistical analyses were performed with Prism 6.04 
software (GraphPad).
Results
Mechano-poration enables rapid delivery of macromolecules to resting, polyclonal B-cells 
without altering function. The process of mechano-poration for loading B-cells with antigen is 
illustrated in Fig. 1A. Live cells are passed through parallel microfluidic channels in a silicon device; in 
Figure 1. Microfluidic cell squeezing provides a robust, scalable method for macromolecule delivery 
to B-cells. A) Schematic representation of microfluidic squeezing for macromolecule delivery to cells. 
Constriction channels were X μ m long (10 or 30 μ m) and Y μ m in diameter (4 or 5 μ m); these values were 
30 μ m long and 4 μ m in diameter unless otherwise indicated. B) Representative histograms and gating 
strategy for assessing device performance for delivery of small (3 kDa) and large (40 kDa) dextrans in B-cells 
under these antigen delivery conditions: untreated; endocytosis; SQZ= squeezed (mechano-poration). C) 
Quantitative analysis of macromolecule uptake into resting B-cells relative to endocytosis; cell viability 
following mechano-poration (n = 7 independent experiments). D) Quantitative analysis of intra-device 
delivery performance (n = 13 consecutive runs using 1 device; results representative of > 3 independent 
experiments). E) Dextran delivery into resting B-cells as a function of cell density from 5-50 million 
B-cells/mL (n = 3 replicates; representative of> 3 independent experiments). All data were represented as 
means± standard deviation. Pairs of conditions were tested in E) for statistically significant differences 
with ordinary 1-way ANOVA followed by Holm Sidak multiple comparisons test; multiplicity adjusted 
p-values < 0.05 were considered significant, but none were found.
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each channel, 1 or more constrictions create transient pores in the membranes of cells passing through 
the device. Macromolecular cargos present in the surrounding fluid can diffuse into the cell during this 
transient poration, leading to intracellular loading. Previously, we demonstrated that mechano-poration 
is effective for promoting cytosolic delivery of macromolecules into a wide variety of cell types including 
primary murine B-cells24; efficient delivery was achieved with 5 sequential constrictions with dimen-
sions 30 μ m length and 5 μ m width. However, recent iterations in device design (increased number 
of parallel constriction channels to 75, longer entry region, reversibility, etc.)36 prompted us to revisit 
optimal mechano-poration parameters for protein delivery into B-cells and subsequent antigen pres-
entation. Pilot optimization experiments showed that 30-4 × 1 microfluidics chips (1 constriction per 
channel that is 30 μ m long and 4 μ m in diameter) run at 120 psi were the most effective chip design for 
mechano-poration of murine B-cells with both efficient delivery and high cell viability at concentrations 
of 5 × 106 B-cells/mL (Supplementary Fig. S1A shows representative delivery of 30-5 × 5 vs. 30-4 × 1); 
these conditions were used for all subsequent delivery experiments. Cells at this pressure ran through 
a device at a rate of approximately 1 million cells per second. We performed a quantitative assessment 
of inter-device and intra-device variability in process efficacy for resting polyclonal murine B-cells, and 
compared the uptake of low and high molecular weight dextrans (3 and 40 kDa, respectively) delivered 
into B-cells via mechano-poration (condition abbreviated as “SQZ” in the figures). In parallel, control 
B-cells were incubated with the same polymers for the duration of mechano-poration (~30 min) to com-
pare levels of internalization achieved by B-cells through steady-state fluid-phase endocytosis/pinocyto-
sis (“endocytosis”). Representative histograms of dextran uptake by B-cells following mechano-poration 
(“SQZ”) vs. controls are shown in Fig. 1B. As shown in Fig. 1C (left), microfluidic squeezing promoted 
greatly enhanced dextran uptake compared to endocytosis, with internalization increased ~65-fold and 
~25-fold for 3 and 40 kDa dextrans, respectively. This represented delivery to 75-90% of all cells for 
both dextrans; by comparison less than 10% of resting B-cells endocytosed detectable amounts of cargo 
(Fig.  1B,D). Viability of recovered cells after mechano-poration was ~95% (Fig.  1C; right), similar to 
endocytosis controls. The manufacturer-specified capacity for the maximum number of cells that can be 
passed through these disposable microfluidic chips ranged from 1-5 million cells per device; however, 
here devices were run with multiple aliquots of cells (1 million cells per run) until clogged, and the 
maximum number of cells run through each individual device in a given experiment was often in sig-
nificant excess of 5 million cells. Importantly, we determined there was low variability in percentage of 
delivered cells from first run to clogging of devices, indicating that intra-device variability was minimal 
(Fig.  1D). We also found that delivery performance of multiple devices within the same experimental 
session (inter-device variability) was very consistent (Supplementary Fig. S1B). Recognizing that some 
applications may require higher numbers of B-cells, we also tested the efficacy of the microfluidic devices 
at different cell densities. The efficiency of intracellular dextran delivery was largely independent from 
cell concentration up to at least 50 × 106 cells per mL, indicating potential for robust scalability (Fig. 1E).
To be effective as APCs for priming effector T-cells, B-cells need to be both loaded with antigen and 
activated, as activation upregulates antigen presentation and the expression of costimulatory receptors 
required for naïve T-cell activation16. By contrast, for promotion of tolerance, un-activated or alter-
natively activated B-cells loaded with antigen may be desirable. Thus, we next assessed whether the 
process of mechano-poration impacts B-cell activation, in the presence or absence of defined B-cell 
stimuli. CpG DNA is a ligand for Toll-like receptor (TLR)-9 that has been extensively explored as a 
vaccine adjuvant and B-cell stimulus that enhances antigen uptake and activates both mouse and human 
cells20,37,38. Using CpG as a model activation stimulus, we longitudinally phenotyped multiple surface 
markers of B-cell activation and antigen presentation to evaluate (i) whether resting B-cells were acti-
vated by mechano-poration and (ii) whether mechano-poration altered the activation of CpG-stimulated 
B-cells. As shown in Figs.  2A-C, microfluidic squeezing did not significantly induce the expression of 
activation (CD69), co-stimulation (CD40, CD86), or antigen presentation (MHC class I, II) markers in 
resting B-cells. Mechano-poration also did not alter the upregulation of these markers induced by treat-
ment with CpG for 48 h (Fig. 2A-C). Thus, alterations induced by the mechanical stress of cell squeezing 
were non-stimulatory for resting B-cells, and squeezed B-cells maintained normal functional responses 
to stimulation. This also held true for other candidate B-cell stimuli including class C CpG oligonucleo-
tides, LPS, and multimeric CD40L (Supplementary Fig. 2).
Polyclonal B-cells squeezed with whole protein expand antigen-specific CD8+T-cells that 
secrete effector cytokines in vitro. To determine whether mechano-poration can facilitate protein 
delivery to the cytosolic class I MHC antigen processing and presentation machinery, we utilized the 
optimal conditions described above to deliver the model protein ovalbumin (OVA) into resting, purified 
polyclonal B-cells, by passing cells through microfluidic device in the presence of excess OVA in the 
surrounding medium. Squeezed B-cells were then co-cultured with CFSE-labelled OT-I CD8+ T-cells, 
which bear a transgenic T-cell receptor specific for the MHC class I-restricted OVA peptide SIINFEKL, 
in the presence or absence of CpG as a B-cell-activating stimulus (Fig.  3A). CFSE dilution in OT-I 
T-cells was analysed by flow cytometry to assess proliferation/expansion of the T-cells in response to 
B-cell-presented antigen (gating strategy presented in Fig.  3B & Supplementary Fig. S3). As positive 
controls, T-cells were cultured with anti-CD3/CD28-coated beads or with B-cells incubated continuously 
with the optimal SIINFEKL peptide; T-cells were cultured alone with no stimulation as negative controls.
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B-cells incubated with OVA in solution to allow antigen uptake by endocytosis for the same dura-
tion as microfluidic squeezing (30 min) elicited no T-cell proliferation above background, regardless 
of whether CpG was subsequently added to activate the B-cells in co-culture (endocytosis, endo-
cytosis+ CpG, Fig.  3C). This weak response was only modestly enhanced by continuous incubation 
of the B/T co-cultures for 4 days with high concentrations of soluble OVA (100 μ g/mL); ~30% of the 
input CD8+T-cells divided with or without B-cell activation by CpG in these conditions (Fig. 3C, OVA 
and OVA+ CpG, respectively). These results are consistent with the low efficiency of endocytic antigen 
uptake and cross presentation by B-cells. Notably, prior studies have also shown that when APCs are 
continuously exposed to antigen and CpG, antigen uptake and cross presentation to T-cells is very lim-
ited unless the antigen and CpG are directly conjugated20,37. By contrast, CD8+T-cells incubated with 
squeezed B-cells proliferated significantly in both resting and activated co-cultures; co-cultures that were 
resting or continuously activated by soluble CpG had approximately 40% and 80% input CD8+T-cells 
undergoing division, respectively (Fig.  3C, p = .038 and < 0.001 vs. endocytosis for resting and CpG, 
Figure 2. B-cell activation are not altered by cell squeezing. Representative pseudocolor 2D plots (A 
CD40 vs. CD86) and histograms (B CD69 and MHC I) from flow cytometry for activation and antigen 
presentation markers of resting or CpG-stimulated B-cells passed through the mechano-poration chip 
or incubated for an equivalent period in media (endocytosis). C) Quantitative analysis of activation and 
antigen-presentation marker expression after 48 h in media alone (resting) or CpG B 1826 stimulation 
(CpG), calculated as fold change in geometric mean fluorescence intensity above resting, endocytosis cells. 
All data were represented as means± standard deviation (n ≥ 3 independent experiments). Pairs of conditions 
were tested in C) for statistically significant differences between SQZ and endocytosis with ordinary 1-way 
ANOVA followed by Holm Sidak multiple comparisons test; multiplicity adjusted p-values < 0.05 were 
considered significant, but none were found.
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Figure 3. Whole protein delivery to B-cells by cell squeezing enables robust MHC class I antigen 
presentation and antigen-specific CD8+T-cell priming in vitro. A) Experimental timeline for antigen 
loading (endocytosis, peptide, or squeezed) on day 0 followed by co-culture with purified, CFSE-
labelled OT-I CD8+T-cells. B) Representative histogram overlay showing data from day 4 proliferation of 
endocytosis+ CpG or SQZ+ CpG co-cultures; green gates were used to calculate percent of divided input 
cells and proliferation indices as described in Methods. C,D) Quantitative analysis of percent divided 
input OT-I CD8+(C) and OT-II CD4+(D) T-cells at day 4 of co-culture. E) Normalized total OT-I CD8+T-
cell counts on day 4 of co-cultures were also calculated as described in Methods. All data were shown as 
means± standard deviation (n = 7 independent experiments for B & D; n = 3 independent experiments 
for D). Pairs of conditions were tested in C), D), and E) for statistically significant pairwise differences 
with ordinary 1-way ANOVA followed by Holm Sidak multiple comparisons test; multiplicity adjusted 
p-values < 0.05 were considered significant, and exact p-values were shown where significant. All conditions 
in D) were significantly lower than positive controls (α CD3/28 beads, peptide).
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respectively). CpG-activated squeezed B-cells stimulated the majority of T-cells to divide by 4 days of 
co-culture, essentially identical to positive controls of T-cells primed by anti-CD3/CD28-coated beads or 
B-cells loaded with saturating amounts of SIINFEKL peptide (Fig. 3C). This result is striking given the 
relative inefficiency of cytosolic antigen processing, and suggests that squeezing led to high levels of anti-
gen uptake that may have saturated MHC class I loading with the target peptide. However, cell squeez-
ing should primarily direct antigen to the cytosol and not endosomal compartments where MHC class 
II loading occurs. Consistent with this, we found neither resting nor CpG-activated mechano-porated 
B-cells were able to expand OVA-specific OT-II CD4+T-cells after 4 days of co-culture (Fig. 3D).
We also assessed proliferation index (the average number of divisions for all dividing cells) and 
counts of recovered T-cells to determine survival of proliferating OT-I cells primed by mechano-porated 
B-cells. Mechano-porated, activated B-cells drove T-cells to undergo progressive division for an aver-
age of ≥ 3 generations, equivalent to the anti-CD3/CD28 bead and SIINFEKL peptide positive controls 
(Supplementary Fig. S4). T-cell counts at day 4 showed that CpG-activated squeezed B-cells promoted 
the best expansion of T-cells by far among the tested groups, yielding 10-fold more OT-I cells than 
activated B-cells loaded with antigen by endocytosis or resting B-cells loaded by squeezing (Fig.  3E). 
Further, more T-cells were recovered from activated/squeezed B-cell co-cultures than cultures of T-cells 
primed with anti-CD3/28-coated beads (a first-line platform for T-cell expansion in adoptive therapy 
clinical trials39), and this group matched the T-cell expansion achieved by B-cells loaded by continuous 
optimal peptide exposure (Fig. 3E).
The functionality of B-cell-primed CD8+ T-cell populations was assayed by measuring secretion of 
effector molecules at days 2 and 4 of co-cultures. B-cells loaded with antigen by squeezing, whether rest-
ing or activated, primed T-cells to secrete substantial quantities of granzyme B, IFN-γ , and TNF-α , while 
B-cells loaded with antigen by endocytosis produced basal levels of cytokines (Fig. 4A). CpG-activated, 
squeezed B-cells primed CD8+ T-cells that produced less granzyme B, but more IFN-γ and TNF-α when 
compared to resting squeezed B-cells, though these differences did not reach statistical significance. IL-2 
and activation-induced release of soluble CD137 were also detected40, consistent with T-cell activation 
by both resting and activated mechano-porated B-cells (Fig. 4A). Effector cytokine secretion levels were 
similar between squeezed B-cells and positive controls--beads or peptide. In addition to T-cell-derived 
cytokines, we also examined potential cytokines in the co-culture milieu that could direct CTL priming 
Figure 4. Squeeze-delivered B-cells prime T-cells to produce effector CTL cytokines, while B-cell stimuli 
program distinct cytokine milieus. A) Secretion of major effector cytokines and molecules (granzyme B, 
IFN-γ , TNF-α , IL-2, CD137) were shown for co-cultures indicating T-cell activation state. B) Differential 
IL-6/IL-10 milieus induced in co-cultures by activating with different B-cell stimuli (n = 3 independent 
experiments for A & B). All data were represented as means± standard deviation. Pairs of conditions were 
tested for statistically significant pairwise differences with repeated measures 1-way ANOVA followed by 
Holm Sidak multiple comparisons test; multiplicity adjusted p-values < 0.05 were considered significant, and 
exact p-values were shown where significant.
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and output. Different B-cell stimuli produced distinct cytokine secretion patterns as expected: CpG- and 
LPS-stimulated cells generated divergent ratios of IL-6 and IL-10 secretion, while mCD40L induced 
low levels of both (Fig. 4B). Thus, B-cells loaded with antigen by mechano-poration primed functional 
effector T-cells and produced an IL-6/IL-10 milieu that is known to be important in programming dif-
ferent priming, expansion, and differentiation potentials for effector41–44 and memory CD8+T-cells45,46. 
Consistent with previous studies, combined IL-6 and IL-10 expression correlated with increased prolif-
eration indices in innate-stimulated (CpG B, CpG C, LPS) co-cultures, while resting (SQZ) co-cultures 
had relatively lower proliferation and produced negligible IL-6/IL-10 (Supplementary Fig. S4).
Squeezed B-cells prime antigen-specific CD8+T-cells in vivo. In addition to having potential as 
an in vitro antigen-specific T-cell expansion platform, B-cells are an alternative to dendritic cells for use as 
cellular vaccines. As proof-of-principle for this application, we adoptively transferred CFSE-labelled OT-I 
CD8+T-cells expressing Thy1.1 as a congenic marker into recipient mice as reporters of antigen pres-
entation. One day later, we injected either resting B-cells immediately after mechano-poration-mediated 
antigen loading, or mechano-poration-loaded B-cells that were subsequently activated for 24 h with CpG 
in vitro. Resting B-cells loaded with antigen by endocytosis were used as controls, either immediately or 
after 24 h of activation with CpG. Four days after B-cell transfer, mice were sacrificed and spleens and 
inguinal lymph nodes were analysed for OT-I proliferation by flow cytometry. Representative results 
and flow cytometry gating are shown in Fig.  5A and Supplementary Fig. S5. Consistent with our in 
vitro results, we found that mechano-porated B-cells were able to elicit division of adoptively transferred 
OT-I T-cells while endocytosis controls showed only basal division. Both CpG-activated and resting 
squeezed B-cells caused OT-I proliferation in spleens (Fig. 5B, ~45% and ~35% divided of injected OT-I 
T-cells with p < 0.001 and p = 0.001 comparing SQZ vs. endocytosis, respectively). CpG-activated and 
resting squeezed B-cells also elicited similarly enhanced OT-I proliferation in lymph nodes compared 
Figure 5. Antigen-specific CD8+T-cell proliferation is primed in vivo by squeeze-delivered B-cells. A) 
Representative gating shown on 2D pseudocolor plot (CD8 vs. Thy1.1) to identify adoptively transferred 
OT-I T-cells, followed by representative histogram overlays of CFSE dilution and gating to identify number 
of divisions. B, C) Quantitative analysis shown for % divided OT-I T-cells in spleens (B) and inguinal 
lymph nodes (C). All data are represented as means± standard deviation (n = 3 animals, representative 
of 3 independent experiments). Pairs of conditions were tested for statistically significant differences 
with ordinary 1-way ANOVA followed by Holm Sidak multiple comparisons test; multiplicity adjusted 
p-values < 0.05 were considered significant and exact p-values were shown where significant.
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to endocytosis B-cells (Fig. 5C, ~40% and ~35% divided of injected OT-I T-cells by CpG B and resting 
squeezed B-cells, respectively; p < 0.001 comparing SQZ vs. endocytosis for both resting and CpG). 
Endocytosis controls showed ~4% baseline division in lymph nodes. These promising results suggested 
that B-cells loaded by microfluidic mechano-poration merit further investigation as an in vivo platform 
for cellular vaccines.
Discussion
B-cells loaded with specific antigens have been proposed as candidate APCs for cell-based vaccines and 
as autologous reagents for expansion of antigen-specific T-cells, with potential advantages over den-
dritic cells in these applications, especially with respect to their ready availability in large numbers from 
peripheral blood and their ability to be further expanded substantially in culture. However, methods for 
efficient antigen loading in B-cells, especially for class I MHC presentation, have been a major barrier 
to development of polyclonal B-cells as APCs for in vitro or in vivo use. Here we have demonstrated 
a simple approach using microfluidic-based mechanical deformation and passive diffusion that ena-
bles robust loading of protein antigens directly to the cytosol of resting or activated B-cells, leading to 
MHC class I presentation of peptides derived from native whole protein. The advantages conferred by 
mechano-poration are numerous, including the potential to deliver native proteins without processing, 
engineering, or modification, the rapid nature of the process, the relatively high efficiency of delivery 
and functional outcomes, and the ability to deliver material to resting cells decoupled from cellular biol-
ogy such as programming stimulus or receptor targeting. Alternate strategies for direct protein loading 
have been attempted, including electroporation, with limited success in standard bulk formats, requiring 
engineered, highly controlled electrical fields47,48. These physical strategies also rely on application of 
energy and forces that may damage proteins, whereas for the fluidic strategy used here, extraordinarily 
high shear flow is required for theoretical protein denaturation and has not been observed49. Most clin-
ical strategies for ex vivo T-cell expansion for adoptive transfer rely on extensive activation and pulsing 
with tumour lysate or peptides using large numbers of PBMC feeder cells, APCs or α CD3/28-coated 
beads50–52. Our data suggest that mechano-porated B-cells may be a useful alternative source for autolo-
gous, antigen-loaded APCs that can either match or exceed performance in CTL expansion and effector 
function compared to other platforms such as beads or peptide pulsing. Further, in vivo priming of 
antigen-specific T-cells by mechano-poration loaded B-cells suggests novel opportunities for combined 
cellular immunotherapies similar to previous clinical strategies pairing genetically engineered T-cells 
with ex vivo prepared APCs50,53.
The ability to deliver whole native protein or polypeptides directly to the cytosol for processing and 
MHC class I presentation enables unbiased presentation of multiple peptides following native antigen 
processing. The microfluidic cell squeezing device should also enable delivery of mixtures of proteins, 
including tumour lysates or other complex protein sources in future applications. This would greatly 
facilitate progression of fields such as personalized vaccines by facilitating loading of tumour biopsy 
lysates. Without the need for extensive genetic engineering, protein engineering, biochemical modifica-
tions, and viral or synthetic packaging of protein, mechano-poration facilitates the use of a wide range of 
targets with fewer concerns about complications such as insert size, charge interactions etc. Aside from 
this study’s focus on proteins, squeezing as a platform is readily multiplexed with other cargoes, provid-
ing access to most existing technologies as previously demonstrated by intracellular delivery of siRNA, 
nanoparticles, antibodies, and transcription factors24. Our demonstration that proteins can be delivered 
for MHC class I processing independently of cell activation status is a major advantage of this approach.
To this point, APC activation stimuli are generally constrained by the requirement that they must 
enable antigen uptake. Our approach enables decoupling of protein loading and cellular programming, 
facilitating independent modulation of each component. This could have broad implications for the 
types of vaccines that can be programmed, such as enabling MHC class I presentation in cytokine envi-
ronments that do not favour endocytic uptake or cross-presentation. Our results of OT-I proliferation, 
and in particular effector cytokine secretion primed by resting squeezed B-cells are interesting consid-
ering the well-documented tolerogenic potential of resting B-cells29,30. Tolerised T-cells exist along a 
functional spectrum including cells that can proliferate in response to initial priming, but are unable 
to secrete cytokines or to respond extensively to subsequent antigen exposures as seen in chronic viral 
infections54, CD3/CD28 re-stimulation in vitro without help55, and tolerance56; future studies should 
focus on elucidating how mechano-poration B-primed T-cells function in light of previous studies. This 
system may enable unique basic biology investigations by increasing the modularity of cellular activation 
and antigenic protein compartmentalization, and allowing antigen loading without introducing con-
founding biological effects on the cell such as may occur when using a viral or other biological vector 
to introduce antigen into APCs. For example, our data indicating divergent IL-6/IL-10 cytokine milieus 
produced by different innate and adaptive immune B-cell stimuli can allow investigation of the biology 
of these pleiotropic molecules produced by B-cell APCs independent of their effects on B-cell antigen 
uptake and MHC class I processing/presentation.
Although cellular mechano-poration has demonstrated much potential, the current iteration of 
the technology has certain technical limitations. For delivery of larger macromolecular cargos, there 
is a trade-off between more aggressive mechano-poration for increased delivery and decreased cell 
viability/increased potential device clogging. Such challenges can potentially be overcome through the 
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development of optimized constriction designs and increasing molar concentration of cargo in solution 
to drive higher diffusion rates. The current device design contains 75 parallel constriction channels, lim-
iting the maximum number of cells processed per device run; future increases in the number of channels 
or operating multiple devices in parallel can dramatically improve throughput. The ease of use and rapid 
processing enabled by our approach (~1 × 106 cells/s rate flow through device,< 2 h for total experiment 
time) can provide a host of benefits for clinical translation. Perhaps most obvious is the reduction in 
time and resources required for preparation of cell-based therapeutics. One prospective implementation 
would be a true bedside preparation process using a self-contained, sterile, consumable device; however, 
the current iteration includes a large external pressure system. The development of low pressure chip 
designs could make a bedside implementation more feasible by creating a smaller fluid control footprint. 
In addition to current technological limitations, one potential biological limitation may be the absence of 
MHC class II presentation and priming of CD4+T-cells. CD4+T-cell help can contribute as an important 
component in developing CD8+T-cell responses, particularly supporting the recall of memory57–59, which 
was not directly tested in our proof-of-concept studies. Future studies might address this limitation sim-
ply by complementing mechano-poration with direct surface MHC II loading of T-helper peptides to 
generate CD4+T-cell help. Alternatively, other modifications and cell stimuli could be utilized to enhance 
MHC class II processing of proteins delivered via mechano-poration.
In our application of B-cells as APCs, the amount of patient blood required to prepare a single-dose 
cellular vaccine would be vastly reduced compared to DC-based approaches, and we can successfully 
avoid time required for protein loading by cellular uptake processes such as endocytosis or pinocytosis. 
Our results in vitro demonstrated significant potential for B-APCs as an alternative platform for expan-
sion of effector CTLs. These squeezed B-cells also functioned as effective APCs in vivo, though many 
factors remain to be optimized here such as ideal B-cell activation stimulus and timing, and establishing 
methods to co-load both MHC class I and class II antigen presentation pathways to generate CD4+ T-cell 
help. Future studies should be designed to address these potential limitations, which are concerns for 
many B-cell-based vaccine approaches.
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